Perimenopause: How to Stop Treatment Safely and Manage the Transition

Why "Stopping Treatment" in Perimenopause Is More Complicated Than It Sounds

Perimenopause is not a single moment. It is a hormonal transition that may last 4 to 8 years, driven by erratic fluctuations in estradiol and progesterone before they settle at post-menopausal lows. Treatments started during this window, whether systemic hormone therapy, low-dose antidepressants, or non-hormonal prescription options, were initiated for a reason. Stopping them requires the same clinical thought as starting them.

The question "when should I stop?" depends on what you are taking, how long you have been on it, and where you are in the transition. A 44-year-old in early perimenopause with severe vasomotor symptoms is in a very different position than a 54-year-old who has now been post-menopausal for two years and whose hot flashes have quieted.

The Biology Behind Symptom Rebound

When you stop systemic estrogen, your hypothalamus and pituitary lose the negative feedback they have adapted to. Gonadotropins (FSH and LH) surge transiently, and the thermoregulatory set point narrows again. This is why up to 50% of women experience a return of vasomotor symptoms after discontinuation, often within weeks. The rebound is not evidence that you are "addicted" to hormones. It reflects normal physiology reasserting itself.

What the Evidence Actually Says About Timing

The 2023 Menopause Society Position Statement on hormone therapy does not set a fixed maximum duration. It states that for women under 60 or within 10 years of menopause onset, the benefit-to-risk ratio for systemic estrogen-progestogen therapy is generally favorable. Continuing therapy past that window is an individual decision, not an automatic stop sign.

Which Treatments Are Most Common in Perimenopause, and What Stopping Each One Looks Like

Different therapies have different discontinuation profiles. Knowing yours matters.

Systemic Hormone Therapy (Estrogen Plus Progestogen or Estrogen Alone)

Systemic HRT is the most effective option for moderate to severe vasomotor symptoms, and it is also the one with the most to plan around at discontinuation.

Tapering vs. Stopping cold. There is no large randomized controlled trial comparing tapered discontinuation to abrupt cessation of HRT for symptom outcomes. The clinical consensus, reflected in ACOG Practice Bulletin 141, favors gradual dose reduction because it gives the hypothalamic-pituitary axis time to readjust. A practical approach: reduce the estrogen dose by one step every 4 to 8 weeks. For transdermal estradiol, moving from 0.1 mg/day to 0.05 mg/day to 0.025 mg/day over 3 to 4 months is a common schedule.

Progestogen matters too. If you are using a combined regimen (estrogen plus a progestogen to protect the uterus), the progestogen is typically tapered alongside estrogen. Stopping estrogen while continuing progestogen alone is not standard practice and offers no vasomotor benefit.

After you stop. Bone density declines accelerate in the first 12 to 24 months post-discontinuation. A baseline DEXA scan before stopping is worth discussing with your clinician, particularly if you are already post-menopausal or have other osteoporosis risk factors.

Low-Dose SSRIs and SNRIs (Paroxetine, Venlafaxine, Desvenlafaxine)

Non-hormonal prescription options for hot flashes carry their own discontinuation considerations.

Paroxetine 7.5 mg (Brisdelle) is the only FDA-approved non-hormonal option specifically for menopausal vasomotor symptoms. Stopping it abruptly at standard antidepressant doses can cause SSRI discontinuation syndrome: dizziness, electric-shock sensations, irritability, and nausea. At the 7.5 mg dose used for hot flashes this risk is lower, but a taper over 2 to 4 weeks is still prudent.

Venlafaxine and desvenlafaxine at the doses used for vasomotor symptoms (37.5 to 75 mg/day) carry a higher discontinuation syndrome risk than SSRIs. Taper over 4 to 8 weeks, reducing by no more than 25% of the current dose every 1 to 2 weeks.

Gabapentin and Pregabalin

Used off-label for vasomotor symptoms, these agents require a gradual taper to avoid rebound anxiety, insomnia, and in rare cases seizure risk at higher doses. The FDA prescribing information for gabapentin recommends reducing the dose over a minimum of one week.

Fezolinetant (Veozah)

Fezolinetant, a neurokinin 3 receptor antagonist approved by the FDA in May 2023, is a non-hormonal option with a different mechanism. Clinical trial data from the SKYLIGHT 1 and SKYLIGHT 2 studies showed meaningful reductions in hot flash frequency and severity, but discontinuation data from these trials did not show a significant rebound effect. Stopping is generally done without a taper, though returning symptoms are common and expected.

Life-Stage Guide: Who Is Stopping, and Why It Differs

Reproductive Years and Early Perimenopause (Ages 40 to 47)

Women in early perimenopause who started treatment for severe cycle-related symptoms, insomnia, or mood changes may reach a point where cycles stabilize temporarily and want to reassess. If you started hormonal therapy primarily to regulate the cycle rather than for classic vasomotor symptoms, a trial off treatment can clarify whether your body has moved further into the transition or whether you are in a lull.

Critically: you may still ovulate sporadically even with significant perimenopausal symptoms. ACOG Committee Opinion 734 and The Menopause Society both note that pregnancy remains possible until 12 consecutive months without a period. If you are stopping systemic HRT at this stage, contraception remains necessary. Low-dose combined oral contraceptives, the hormonal IUD, or progestogen-only methods are all compatible with this life stage and continue to offer cycle control alongside contraception.

Mid-Perimenopause (Ages 47 to 52)

This is the window of maximum hormonal variability and, for many women, peak symptom burden. Stopping treatment in this window often leads to symptom return. If you want to try stopping, the window right after a natural lull in symptoms (rather than during a symptom spike) gives the best chance of tolerating the transition.

Post-Menopause (12 or More Months After the Last Period)

Most women who want to stop systemic HRT are in this group. The 2023 Menopause Society guidance does not mandate stopping at any particular post-menopausal age but notes that for women over 60 or more than 10 years from menopause, the absolute cardiovascular and breast risk profile shifts and should be re-evaluated annually.

If vasomotor symptoms have genuinely resolved (typically 4 to 5 years post-menopause for most women, though 10 to 15% continue to have symptoms into their 60s and beyond), this is a reasonable time to attempt a supervised taper. If symptoms persist, continuing therapy is a legitimate choice, not a delay.

The Practical Taper: A Step-by-Step Framework

This framework synthesizes current society guidance with clinical practice patterns at WomanRx. It is not a substitute for individualized advice from your prescriber.

Step 1: Confirm you are ready. "Ready" means symptoms have been stable for at least 3 consecutive months on your current dose. Do not start a taper during a high-stress period, a hot summer if your symptoms are heat-triggered, or while managing a new medical diagnosis.

Step 2: Map your regimen. List every component: estrogen type, dose, delivery route, progestogen type and dose, and any adjunct (gabapentin, SSRI). Taper each component methodically, not all at once.

Step 3: Choose your taper schedule. For transdermal estradiol: reduce by one dose tier every 4 to 8 weeks. Standard tiers are 0.1 mg, 0.075 mg, 0.05 mg, 0.025 mg, and then off. For oral estradiol: reduce by 0.5 mg every 4 to 8 weeks. For conjugated equine estrogen: step down from 0.625 mg to 0.3 mg over 4 to 8 weeks, then stop.

Step 4: Track symptoms weekly. A simple log of hot flash frequency and severity (0 to 10), sleep quality, and mood gives you and your clinician objective data. The Menopause Rating Scale is a validated 11-item tool you can complete in under two minutes.

Step 5: Build in a pause-and-reassess point. If symptoms become severe at any dose step, hold at that dose for 4 to 8 weeks before continuing the taper. Pushing through severe rebound is not clinically necessary.

Step 6: Plan your post-stop monitoring. Schedule a clinician check-in 6 to 8 weeks after your final dose. If you have not had a DEXA scan in the past 2 years and are stopping systemic estrogen, discuss whether one is indicated now.

What Happens to Your Bones, Cardiovascular System, and Brain After Stopping

Bone Health

Systemic estrogen maintains bone mineral density by inhibiting osteoclast activity. When you stop, that protection fades. A 2021 analysis in the Journal of Bone and Mineral Research found that women who discontinued HRT had bone loss rates similar to newly post-menopausal women in the first 2 years after stopping, regardless of how long they had been on therapy. This does not mean you need to stay on HRT forever for bone protection. Other options, including weight-bearing exercise, adequate calcium and vitamin D, and in some cases bisphosphonate therapy, can maintain density after HRT ends. Discuss your 10-year fracture risk using the FRAX tool with your clinician before stopping.

Cardiovascular Risk

The Women's Health Initiative (WHI) showed that systemic estrogen-progestogen therapy in older post-menopausal women increased cardiovascular event risk, but subsequent re-analyses confirmed that women who started HRT within 10 years of menopause or before age 60 (the "timing hypothesis") did not share this risk profile. Stopping HRT does not reset cardiovascular risk to zero. Your underlying lipid profile, blood pressure, glucose tolerance, and lifestyle factors remain the dominant drivers.

Cognitive Health and Mood

The relationship between estrogen and cognition in perimenopause is an active area of research. The SWAN study showed that verbal memory declines during perimenopause and tends to stabilize in post-menopause. Whether stopping HRT accelerates any cognitive change is not established with certainty in current trial data. Women with a history of depressive episodes during perimenopause may notice mood changes after stopping, particularly if they were using systemic estrogen partly for mood stabilization. This is worth discussing explicitly with your prescriber before discontinuation.

Pregnancy, Contraception, and Perimenopause: A Required Conversation

This section applies if you are still in perimenopause and have not yet reached 12 consecutive months without a period.

You can still get pregnant in perimenopause. Ovulation, while irregular and less frequent, continues until the final menstrual period is confirmed in retrospect. ACOG Practice Bulletin 141 explicitly notes that unintended pregnancy rates in women aged 40 to 44 are higher than commonly assumed, and women in this age group account for a meaningful proportion of unintended pregnancies.

Hormone therapy is not a contraceptive. Standard perimenopausal HRT doses of estrogen are far lower than contraceptive doses and do not reliably suppress ovulation. If you are stopping HRT and are sexually active with a uterus and ovaries, contraception is not optional until menopause is confirmed.

Safe contraceptive options during perimenopause:

• Levonorgestrel IUD (Mirena): provides progestogen-based endometrial protection, reduces menstrual bleeding, and can serve as the progestogen component of an HRT regimen while also providing contraception.
• Copper IUD: non-hormonal, highly effective, appropriate if you are avoiding all hormonal methods.
• Progestogen-only pill (mini-pill): appropriate for women with contraindications to estrogen-containing contraceptives.
• Combined oral contraceptives (low-dose): appropriate for non-smoking women under 50 with no cardiovascular risk factors; also suppresses perimenopausal cycle irregularity.

When to stop contraception. FSH measured on two occasions at least 6 weeks apart, both above 30 IU/L in a woman over 50 who has been amenorrheic for 12 months, is the conventional threshold for confirming menopause and discontinuing contraception. Faculty of Sexual and Reproductive Healthcare (FSRH) guidance advises continuing contraception for 12 months after the last menstrual period in women over 50, and 24 months in women under 50.

Pregnancy safety of common perimenopause treatments. Systemic estrogen-progestogen HRT is not approved for use in pregnancy and should be stopped as soon as pregnancy is confirmed. Venlafaxine and paroxetine both carry FDA pregnancy safety data showing neonatal adaptation syndrome risk with third-trimester exposure; paroxetine has a specific FDA warning regarding cardiac defects with first-trimester use. Gabapentin crosses the placenta; a 2020 meta-analysis in Neurology found associations with preterm birth. None of these drugs are appropriate to continue in pregnancy without specialist obstetric review.

Who Should Consider Stopping Treatment Now vs. Who Should Stay on It

Reasonable Candidates for Stopping

• Women who have been post-menopausal for 4 or more years and whose vasomotor symptoms have substantially improved.
• Women who have developed a new contraindication (new diagnosis of hormone receptor-positive breast cancer, unexplained vaginal bleeding awaiting investigation, or active thromboembolic disease).
• Women who have reached their personal risk-benefit reassessment point after shared decision-making with their clinician.

Women Who May Benefit From Continuing

• Women with persistent moderate to severe vasomotor symptoms (hot flashes more than 7 per day, or any hot flashes rated severe on a validated scale) at any post-menopausal age, after risk reassessment.
• Women with early surgical menopause (bilateral oophorectomy before age 45) who are under 51, the average natural menopause age. The Menopause Society recommends systemic HRT in this group until at least the age of natural menopause unless there is a specific contraindication.
• Women with documented low bone mineral density (T-score below -2.0) and no alternative bone-protective therapy in place.
• Women who are managing genitourinary syndrome of menopause (GSM) with systemic therapy and for whom local vaginal estrogen alone is insufficient.

Genitourinary Syndrome of Menopause: A Separate Conversation From Systemic HRT

One of the most important distinctions to understand: stopping systemic HRT does not mean you must stop all estrogen therapy. Genitourinary syndrome of menopause (GSM) affects an estimated 27 to 84% of post-menopausal women and causes vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs. Unlike vasomotor symptoms, GSM does not improve with time. It typically worsens without treatment.

Local vaginal estrogen (cream, tablet, ring, or the newer prasterone/DHEA suppository and ospemifene oral tablet) delivers estrogen at very low systemic levels. Systemic absorption from local vaginal estrogen is so minimal that it does not require a progestogen to protect the uterus. ACOG Practice Bulletin 141 states that local vaginal estrogen is safe for most women, including most breast cancer survivors, at the doses used for GSM.

You can stop systemic HRT and continue local vaginal estrogen indefinitely. These are two separate decisions.

Managing Perimenopause Without Medication: Evidence-Based Supports

Not every woman uses prescription therapy, and not every woman who stops prescription therapy is left with nothing. Several behavioral and non-prescription approaches have meaningful evidence behind them.

Cognitive behavioral therapy (CBT) for hot flashes. The MENOS 1 trial showed that CBT delivered via a self-help book reduced the personal bother of hot flashes significantly compared to usual care in post-menopausal women. The mechanism is not placebo. CBT appears to modify the cognitive and emotional response to vasomotor events, reducing their impact even when frequency does not change dramatically.

Paced breathing and mindfulness. Evidence is weaker and effect sizes smaller than for CBT, but both are low-risk and may benefit women whose hot flashes are triggered by stress.

Weight management. Women with a BMI <30 have lower hot flash frequency than heavier women. Losing 10 pounds in the SWAN study cohort was associated with a greater likelihood of vasomotor symptom improvement. This is not a directive to lose weight for cosmetic reasons. It is evidence that metabolic health affects symptom burden.

Exercise. The data on aerobic exercise directly reducing hot flash frequency is mixed. The MsFLASH CARDIO trial found no significant reduction in hot flash frequency with aerobic exercise compared to control. Exercise does, however, meaningfully improve sleep quality, mood, cardiovascular risk factors, and bone density, all relevant when stopping HRT.

Phytoestrogens and supplements. Evidence for soy isoflavones, black cohosh, and red clover is inconsistent. A 2013 Cochrane review of phytoestrogens found a statistically significant but clinically modest reduction in hot flash frequency (approximately one fewer hot flash per day compared to placebo). They are not a replacement for HRT in women with moderate to severe symptoms.

Monitoring After You Stop: What to Track and When to Check Back In

Stopping treatment is not the end of clinical contact. Plan for the following:

• 6 to 8 weeks post-stop: clinician check-in to assess symptom severity and whether the taper was tolerated. This is also the time to discuss whether symptoms warrant restarting.
• 6 months post-stop: cardiovascular risk factor check (blood pressure, fasting glucose if indicated, lipids if not recently checked).
• 12 months post-stop (or at the next scheduled visit): bone density assessment if you stopped systemic estrogen and have not had a DEXA in 2 or more years, or if you have additional osteoporosis risk factors.
• Ongoing: annual review of GSM symptoms, urinary symptoms, and sexual health. These do not resolve on their own and should not be left unaddressed.

The 2023 Menopause Society Position Statement summarizes it directly: "There is no arbitrary limit to the duration of therapy; decisions should be individualized based on the specific risks and benefits."